Kazia Therapeutics Annual Report 2021

STATEMENT OF CHANGES IN EQUITY For the year ended 30 June 2021 2021 AT A GLANCE CHAIRMAN’S LETTER CEO’S REPORT KEY MILESTONES PIPELINE REVIEW PARTNER FOR SUCCESS WORK WITH THE BEST #2 IN THE KAZIA STORY FINANCIAL REPORTS Kazia Therapeutics Limited Annual Report 2021 39 Contributed equity Other contributed equity Foreign currency translation reserve Share based payments reserve Accumulated losses Total equity Consolidated $ $ $ $ $ $ Balance at 1 July 2019 36,641,519 464,000 (451,668) 2,489,121 (24,948,206) 14,194,766 Loss after income tax benefit for the year - - - - (12,467,466) (12,467,466) Other comprehensive income for the year, net of tax - - (3,520) - - (3,520) Total comprehensive income for the year - - (3,520) - (12,467,466) (12,470,986) Shares issued (note 17) 12,972,747 - - - - 12,972,747 Share issue costs (note 17) (833,052) - - - - (833,052) Transactions with owners in their capacity as owners: Share-based payments (note 32) - - - 262,105 - 262,105 Expired options - - - (1,230,115) 1,230,115 - Balance at 30 June 2020 48,781,214 464,000 (455,188) 1,521,111 (36,185,557) 14,125,580 The above statement of changes in equity should be read in conjunction with the accompanying notes